Bulk Inquiry
EAI045
- Soluble in DMSO
- MF: C19H14FN3O3S
- MW: 383.4
Description
EAI045 is an allosteric inhibitor that targets drug-resistant L858R/T790M-mutant EGFR tyrosine kinase (IC50 value of 3 nM), and spares the wild-type receptor (~1000-fold selectivity versus wild-type EGFR at 1 mM ATP).
More Information
| Parent CAS No. | 1942114-09-1 |
|---|---|
| Chemical Name | 2-(5-Fluoro-2-hydroxyphenyl)-2-(1-oxoisoindolin-2-yl)-N-(thiazol-2-yl)acetamide |
| SMILES | C1(O)C(C(N2CC3C=CC=CC=3C2=O)C(=O)NC2=NC=CS2)=CC(F)=CC=1 |
| MFCD | N.A. |
| InChi | InChI=1S/C19H14FN3O3S/c20-12-5-6-15(24)14(9-12)16(17(25)22-19-21-7-8-27-19)23-10-11-3-1-2-4-13(11)18(23)26/h1-9,16,24H,10H2,(H,21,22,25) |
| InChiKey | YTUFHOKUFOQRDF-UHFFFAOYSA-N |
| CID | 121231412 |
| Short Description | Allosteric EGFR L858R/T790M inhibitor |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1128 | Erlotinib hydrochloride |
From $77.00 |
| 1358 | BIRB 796 |
From $71.50 |
| 1393 | Gefitinib |
From $77.00 |
| 1395 | Lapatinib ditosylate |
From $88.00 |
| 1398 | Sunitinib malate |
From $88.00 |
| 1411 | Vandetanib |
From $55.00 |
| 1414 | AG 013736 |
From $55.00 |
| 1420 | Pazopanib hydrochloride |
From $66.00 |
| 1433 | CI 1033 |
From $66.00 |
| 1461 | Cediranib |
From $77.00 |
| 1506 | WZ 4002 |
From $77.00 |
| 1526 | Neratinib |
From $88.00 |
| 1544 | BIBW 2992 |
From $55.00 |
| 1547 | OSI 930 |
From $99.00 |
| 1632 | OSI 420 |
From $99.00 |
| 1637 | Vatalanib |
From $82.50 |
| 1638 | ABT 869 |
From $88.00 |
| 1653 | AEE 788 |
From $88.00 |
| 1662 | CP 547632 |
From $77.00 |
| 1665 | Pelitinib |
From $99.00 |
| 1667 | SU 5402 |
From $66.00 |
| 1678 | Regorafenib |
From $77.00 |
| 1717 | Tivozanib |
From $88.00 |
| 1760 | EGFR Inhibitor [879127-07-8] |
From $132.00 |
